Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis

NCT06763367 · tracked via the Priya Life Science China tracker

Sponsor

Nanjing First Hospital, Nanjing Medical University

Phase

Not applicable

Started

2025-01-08

Last updated

2025-01-08

Condition(s) studied

RosaceaAcneCentellaMelasma

Investigational drug(s) / intervention(s)

Face mask containing Centella sinensis

Face mask containing Centella sinensis: A half-face control test was used in this study. One side of the face was treated with a mask containing Asiaticum asiatica and the other side was treated with a mask without Asiaticum asiatica

Study summary

The purpose of this study was to investigate the efficacy and safety of repairing facial mask containing Asiaticum asiatica in treating disjunctive skin diseases. A multi-center randomized double-blind self-half face control method was used. A computer-generated randomization method was used. Each cheek was randomly assigned to receive the snow glycoside mask and the control group.

Eligibility

Sex

ALL

Min age

18 Years

Max age

60 Years

Healthy volunteers

Inclusion Criteria: 1. Meet mild to moderate rosacea, acne diagnostic criteria; Meet the diagnostic criteria for melasma; 2. Over 18 years of age; 3. Be able to follow the treatment rules of the study and be followed for 8 weeks; 4. Informed consent; 5There were no significant cardiac, liver, kidney, gastrointestinal, neurological, psychiatric, or metabolic disorders 6.No medication was used within 1 month Exclusion Criteria: 1. Currently pregnant, planning to become pregnant or breastfeeding; 2. Documented hypersensitivity to any active ingredient or excipient included in the study drug, or a history of adverse reactions to cosmetic products; 3. Participate in other clinical studies within 3 months before the start of the study; 4. Frequent use of Chinese medicine, sleeping pills, sedatives, anti-anxiety drugs or potentially addictive substances; 5. Present with concomitant skin conditions that may confuse the clinical assessment of rosacea, melasma, seborrheic dermatitis or pose a risk to participants, or have a history of severe skin conditions; 6. Normal use of relevant treatment (including intense pulsed light, pulsed fuel laser, oral and topical tranexamic acid, oral tetracycline antibiotics, oral compound glycyrrhizin and other anti-inflammatory drugs) 7. Patients with incomplete observation data, incomplete course of treatment and inability to take drugs as prescribed by doctors were removed

Primary outcome measure(s)

Clinical erythema Score (CEA) — Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment.
Clinical erythema score (CEA) was divided into no, mild, moderate and severe according to the severity of rosacea, corresponding to 0,1,2,3, respectively.
Global Aesthetic Improvement Scale Score (GAIS) — Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment.
The Global Aesthetic Improvement Scale (GAIS) score was evaluated by the treating physician and divided into four levels: very improved corresponding, substantial improvement, improvement, no change; Corresponding to the best beauty effect, significant improvement but not the best, significant improvement, no change;
Melasma Area and Severity Rating (MASI) — Patients were followed up on the day of treatment and at 1, 2, 3, 4, 6, and 8 weeks after treatment.
The melasma Area and Severity Rating (MASI) is used to evaluate the severity of melasma. Melanin deposition was quantitatively evaluated from three aspects: area, color depth and color uniformity. Area weight: Forehead 30%, left cheek 30%, right cheek 30%, mandibular 10%, color plaque proportion (A) \< 10% recorded 1 points, 10% \~ 29% recorded 2 points, 30% \~ 49% recorded 3 points, 50% \~ 69% recorded 4 points, 70% \~ 89% recorded 5 points, 90% \~ 100% recorded 6 points; Color depth (D), color uniformity (H) scores range from 0 to 4 points, no score 0 points, slight score 1 points, moderate score 2 points, obvious score 3 points, maximum score 4 points. MASI score = forehead \[0.3A (D+H)\]+ right cheek \[0.3A (D+H)\]+ left cheek \[0.3A (D+H)\]+ mandibular \[0.1A (D+H)\], score range 0 \~ 48, score was positively correlated with melanin deposition.

Trial sites (1)

Facility	City	Region	Status
Nanjing First Hospital	Nanjing	Jiangsu

More Nanjing First Hospital, Nanjing Medical University trials in China

Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients Recruiting

The Effect of Bupivacaine Liposome Preemptive Analgesia on Postoperative Pain and Delirium in Elderly Patients Undergoing Hip Fracture Surgery Starting soon

Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA) Recruiting

Different Injection Speed on Local Anaesthetic Spread of ESPB Recruiting

Effect of Subanesthetic Dose of Esketamine on Sleep Quality Recruiting

Other trials for the same condition

Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne Recruiting

Emulsion 8-Week Anti-acne Efficacy Clinical Study Active, not recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne Recruiting

Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety Recruiting

Microfocused Ultrasound for Facial Pigmentary Diseases and Rosacea Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06763367 on ClinicalTrials.gov ↗ ← All trials in China